https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease

BEAM-101 Receives RMAT for the Treatment of Sickle Cell Disease

The designation is supported by promising results from the ongoing phase 1/2 BEACON clinical trial.

administrator

Related Articles